I have been sitting on a number of obituaries and news stories about fellow myeloma patients who have passed-away recently.

Mixed-in with a lot of new research teasers from the upcoming ASCO meetings in Chicago, a number of significant and touching eulogies and several inspirational stories of myeloma warriors like you and me, I thought I would share some thoughts from readers about myeloma philosophy.

Trade names normally aren’t established and trademarked until after FDA preliminary approval of a drug.  Looks like our friends at Onyx are pretty confident that the FDA will step-up and quickly approve carfilzomib for relapsed/refractory myeloma patients.

Two weeks ago I had the opportunity to fly down to New Orleans and speak to a group of oncology nurses on behalf of the Institute for Medical Education and Research (IMER).

Today is a travel day.   The first day of a very busy week.

This past week I experienced two extraordinary acts of healthcare kindness in unexpected ways.

Concerned about FDA secondary cancer warnings when using Revlimid?

Remember Andy, the Crazy Guy on a Bike I wrote about last month:

I ended Tuesday’s heartfelt, personal post this way:

I need to put details about my own story–and RVD “light,” on hold for a day to discuss some breaking news with you.

Yesterday I closed my post with this cryptic statement:

When perifosine failed to extend overall survival (OS) in patients with metastasized colorectal cancer recently in a Stage 3 trial, company officials and financial analysts speculated that plans to start a stage 3 multiple myeloma theory might be scrapped:

Did you happen to read the comment from Terry yesterday following my post slamming skeletal surveys?  Just in case you missed it…

I have already heard from several fellow myeloma patients that are willing to share their stories after reading Friday’s post:

Normally I would relegate information like this to my MyelomaNews.com site.  But this is important–really important.

Are you over 70 years of age?  Have an interesting story to share as a patient and/or caregiver?

Multiple myeloma researchers have spent the last decade trying to determine which patients are high risk and less likely to respond favorably to treatment.

Two weeks ago I wrote a three part travelogue about a trip Pattie and I took to Universal Resort in Orlando, Florida. 

This story is very close to my heart.  Not only is Don Wright a close friend, but former NFL football player, Elijah Alexander, and I became friends before he died a a year or so ago.